Novartis AG (NVS) Given Buy Rating at JPMorgan Chase & Co.
Other equities analysts have also issued reports about the stock. Chardan Capital reduced their target price on shares of Novartis AG from $95.00 to $92.00 and set a buy rating on the stock in a research report on Monday. Zacks Investment Research raised shares of Novartis AG from a sell rating to a hold rating in a research report on Wednesday, June 15th. TheStreet lowered shares of Novartis AG from a buy rating to a hold rating in a research report on Wednesday, September 28th. Bank of America Corp. reaffirmed a hold rating on shares of Novartis AG in a research report on Tuesday, July 12th. Finally, Argus reaffirmed a hold rating on shares of Novartis AG in a research report on Thursday, August 25th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Novartis AG presently has a consensus rating of Hold and a consensus target price of $91.33.
Shares of Novartis AG (NYSE:NVS) traded down 0.94% during mid-day trading on Monday, hitting $77.02. The stock had a trading volume of 900,534 shares. The stock has a market cap of $183.40 billion, a P/E ratio of 27.50 and a beta of 0.57. The company’s 50 day moving average is $79.80 and its 200-day moving average is $78.99. Novartis AG has a 52-week low of $69.90 and a 52-week high of $95.11.
Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The company had revenue of $12.47 billion for the quarter, compared to analyst estimates of $12.33 billion. During the same period in the prior year, the company posted $1.25 EPS. On average, equities research analysts anticipate that Novartis AG will post $4.72 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Investment Consultants LLC boosted its position in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the last quarter. Whitnell & Co. boosted its position in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares during the last quarter. Iowa State Bank purchased a new position in Novartis AG during the second quarter worth $122,000. M&R Capital Management Inc. purchased a new position in Novartis AG during the second quarter worth $122,000. Finally, WFG Advisors LP boosted its position in Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the last quarter. 9.78% of the stock is owned by institutional investors.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.